Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 February 2021 | Story André Damons | Photo Charl Devenish
Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

A researcher in the field of drug discovery and development at the University of the Free State (UFS) has been appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed as a member of the NHREC council in 2013, and later became the chairperson of the NHREC’s Norms and Standards Committee responsible for developing and revising guidelines for health research. Prof Sekhoacha was appointed deputy chairperson of the council in 2018 and has played an integral part in setting ethical standards for conducting health research in the country.

 Responsibilities of the NHREC

The NHREC is the national statutory body responsible for the governance and advancement of health research ethics in South Africa. Some of the responsibilities of the council are to set ethical norms and standards for health research by developing and revising the guidelines pertaining to health research; to promote and monitor compliance with existing regulations by health research ethics committees; and to build capacity in research ethics committees through robust registration and audit processes.

These responsibilities of the NHREC rest on the need to ensure ethical integrity in research involving human participants and animal subjects, and that research is based on sound scientific and ethical principles.

“It is an honour for me to serve on the NHREC for the third term. The NHREC has achieved remarkable outputs over the past three years, and I believe, given the current composition of the council members, this momentum will not be lost. One of the goals of the NHREC is to further broaden the scope of the ethics in health research guidelines from ‘biomedical research’ to ‘health-related research’ to ensure that adequate guidance is provided for those in health-related disciplines, as a response to the changing environment of research involving humans and the broader meaning of health research.” 

“We need more comprehensive guidelines with nuanced commentaries to indicate how the ethical principles that emanated from biomedical research involving humans, could be effectively implemented in other disciplines of health-related research,” says Prof Sekhoacha. 

Global paradigm shift in role and integration of ethics in health research

Having been a council member since 2013, Prof Sekhoacha, whose training spans from pre-clinical laboratory experimentation, the use of animals in research, clinical trials, and working with indigenous communities, says there is a global paradigm shift in the role and integration of ethics in health research in almost all aspects of research, with an increased emphasis on the scientific and social value of research: the prospect of generating the knowledge in a manner that protects and promotes people's health. Considerations of the NHREC go beyond developing ethical guidelines or ensuring the efficient functioning of the ethics committees, to raising awareness among research institutions and researchers to continually promote ethically sound research conduct. 

The subject of ethics in health research is pivotal and reflective of the values of both the institution and the country at large. 

UFS uses Prof Sekhoacha’s expertise on ethics

Prof Sekhoacha is also a co-opted advisory member in the Senate Research Ethics Committee of the UFS and facilitates workshops and seminars on research ethics offered by the Postgraduate School.

Prof Corli Witthuhn, Vice-Rector: Research and Internationalisation, says it is a great honour for the UFS that Prof Sekhoacha has been elected chair of the NHREC.  “The NHREC governs the research ethics processes in South Africa, and it is strategically important for the UFS to now have one of our own academics play such a nationally important role.  We have been using Prof Sekhoacha’s expertise on issues of ethics and we are looking forward to working with her to continue to better our own ethics processes.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept